Ownership and insider activity for Quest Diagnostics Incorporated (DGX): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing.
Price
| Price | $247.06 (closing price, November 3, 2026) |
| Market Cap | $27.3B |
| Exchange | NYSE |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-26 | PFEIFFER GARY M | S-Sale | 1,203 | $292K |
| 2026-10-21 | CARTER ROBERT B | L-Small | 10 | $2K |
| 2026-10-21 | SAMAD SAM | A-Award | 90 | $21K |
| 2026-10-21 | Gregg Vicky B | A-Award | 63 | $15K |
| 2026-10-21 | KUPPUSAMY KARTHIK | L-Small | 33 | $8K |
| 2026-10-21 | Lassiter Wright III | L-Small | 6 | $1K |
| 2026-10-21 | Plewman Patrick | L-Small | 41 | $10K |
| 2026-10-21 | MAIN TIMOTHY L | L-Small | 18 | $4K |
| 2026-10-21 | DELANEY MARK E | L-Small | 25 | $6K |
| 2026-10-01 | WENTWORTH TIMOTHY C | A-Award | 135 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $359.0M | $137.0M | $135.0M | $1.19B | $1.16B | $872.0M | $315.0M | $686.0M | $549.0M | $420.0M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $926.0M | $924.0M | $1.01B | $1.06B | $1.52B | $1.44B | $1.20B | $1.21B | $1.30B | $1.41B |
| Inventory | $82.0M | $95.0M | $99.0M | $123.0M | $223.0M | $208.0M | $192.0M | $190.0M | $188.0M | $189.0M |
| Total Current Assets | $1.53B | $1.31B | $1.39B | $2.49B | $3.06B | $2.74B | $1.90B | $2.37B | $2.39B | $2.38B |
| Property, Plant & Equipment | $1.03B | $1.15B | $1.29B | $1.97B | $2.23B | $2.30B | $2.35B | $2.42B | $2.76B | $2.86B |
| Goodwill | $6.00B | $6.33B | $6.56B | $6.62B | $6.87B | $7.09B | $7.22B | $7.73B | $8.86B | $8.95B |
| Intangible Assets | $949.0M | $1.12B | $1.21B | $1.12B | $1.17B | $1.17B | $1.09B | $1.17B | $1.76B | $1.64B |
| Total Assets | $10.10B | $10.50B | $11.00B | $12.84B | $14.03B | $13.61B | $12.84B | $14.02B | $16.15B | $16.23B |
| Accounts Payable | $261.0M | $224.0M | $222.0M | $263.0M | $446.0M | $357.0M | $324.0M | $378.0M | $287.0M | $1.60B |
| Short-term Debt | $6.0M | $107.0M | $562.0M | $1.04B | $296.0M | $269.0M | $247.0M | $585.0M | $937.0M | $678.0M |
| Total Current Liabilities | $981.0M | $1.06B | $1.49B | $1.99B | $1.78B | $1.75B | $1.55B | $1.81B | $2.17B | $2.28B |
| Long-term Debt | $3.72B | $3.75B | $3.40B | $3.94B | $3.99B | $4.01B | $3.98B | $4.41B | $5.60B | $5.70B |
| Total Liabilities | $5.36B | $5.47B | $5.66B | $7.08B | $7.13B | $7.05B | $6.83B | $7.60B | $9.26B | $8.94B |
| Retained Earnings | $6.61B | $7.14B | $7.60B | $8.17B | $9.30B | $7.65B | $8.29B | $8.82B | $9.36B | $9.99B |
| Total Equity | $4.63B | $4.92B | $5.22B | $5.64B | $6.76B | $6.44B | $5.89B | $6.31B | $6.78B | $7.17B |
| Total Debt | $3.73B | $3.85B | $3.99B | $5.42B | $4.81B | $4.77B | $4.71B | $5.50B | $7.09B | $6.92B |
| Net Debt | $3.38B | $3.72B | $3.86B | $4.22B | $3.65B | $3.90B | $4.40B | $4.81B | $6.54B | $6.50B |
| Working Capital | $550.0M | $249.0M | -$95.0M | $500.0M | $1.28B | $988.0M | $347.0M | $557.0M | $223.0M | $100.0M |
Financial Health
| Debt / Equity | 0.82 |
| Current Ratio | 1.70 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 3.17 |
Profitability
| Return on Equity | 15.21% |
| Return on Invested Capital | 8.56% |
| Return on Assets | 6.56% |
| Gross Margin | 33.15% |
| Operating Margin | 14.59% |
| Net Margin | 9.53% |
Related companies: NTRA · ILMN · GH · RDNT · GRAL · LH · RVTY · QGEN
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of DGX: Overview · Financials · Valuation · Estimates · Technical
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks